TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study.

Saved in:
Bibliographic Details
Title: TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study.
Authors: Yang XG; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Deng LW; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Zhao Y; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China., Peng B; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China., Liu B; Department of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China., Feng SF; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China., Liu DX; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China., Liu JF; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Sun YY; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Chen Y; Department of pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Liao CL; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Zhang C; Department of Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Liu L; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China., Cao L; Department of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China. 327511253@qq.com., Ren Y; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China. ir_cd_2nd_ph@sina.com., Wei G; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China. weiguo69@sohu.com., Xu GH; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. xgh0913@hotmail.com.
Source: Hepatology international [Hepatol Int] 2026 Apr; Vol. 20 (2), pp. 384-395. Date of Electronic Publication: 2026 Feb 17.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 101304009 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-0541 (Electronic) Linking ISSN: 19360533 NLM ISO Abbreviation: Hepatol Int Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1936-0541
DOI:10.1007/s12072-026-11052-0